Evidence map›Paper›PMID 36112174›Full record

ArticleRadiologie (Heidelberg, Germany)2022

[Oncological theranostics in nuclear medicine].

Christina Laschinsky, Ken Herrmann, Wolfgang Fendler, Michael Nader, Harald Lahner, Boris Hadaschik, Patrick Sandach

Abstract read
PubMed Publisher
In one paragraph

Article in Radiologie (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Effect ofGland surgery · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christina LaschinskyKlinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland. christina.laschinsky@uk-essen.de.
Ken HerrmannKlinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland.
Wolfgang FendlerKlinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland.
Michael NaderKlinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland.
Harald LahnerKlinik für Endokrinologie, Diabetologie und Stoffwechsel, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Deutschland.
Boris HadaschikKlinik für Urologie, Universitätsklinikum Essen, Essen, Deutschland.
Patrick SandachKlinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The theranostic principle describes the diagnostic and therapeutic use of radioactive nuclides linked to biochemically active ligands. The oldest and most prominent field of application of theranostics in oncology is differentiated thyroid cancer treated by radioiodine therapy, which allows imaging of the iodine uptake and thus tumor manifestations by gamma (γ) radiation of radioiodine. Other areas of application include neuroendocrine tumors, castration-resistant prostate cancer and, in the context of individual therapeutic approaches, fibroblastic tumors. Imaging with beta-plus (β

Indexed as

Nuclear MedicineProstatic NeoplasmsHumansIodine RadioisotopesLigandsMalePositron-Emission TomographyPositron Emission Tomography Computed TomographyPrecision MedicineRadiopharmaceuticalsTheranostic NanomedicineIodine RadioisotopesLigandsRadiopharmaceuticalsNeuroendocrine tumorsPositron emission tomography computed tomographyProstateRadioligand therapyThyroid gland

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.